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A B S T R A C T
Purpose
The aim of this work was to develop a clinical practice guideline for the prevention and treatment of
Clostridium difficile infection (CDI) in children and adolescents with cancer and pediatric hemato-
poietic stem-cell transplantation (HSCT) patients.
Methods
An international multidisciplinary panel of experts in pediatric oncology and infectious diseases with
patient advocate representation was convened. We performed systematic reviews of randomized
controlled trials for the prevention or treatment of CDI in any population and considered the directness
of the evidence to children with cancer and pediatric HSCT patients. We used the Grading of Rec-
ommendations Assessment, Development, and Evaluation approach to generate recommendations.
Results
The panelmade strong recommendations to administer either oral metronidazole or oral vancomycin
for the initial treatment of nonsevere CDI and oral vancomycin for the initial treatment of severe CDI.
Fidaxomicin may be considered in the setting of recurrent CDI. The panel suggested that probiotics
not be routinely used for the prevention of CDI, and that monoclonal antibodies and probiotics not be
routinely used for the treatment of CDI. A strong recommendation to not use fecal microbiota
transplantation was made in this population. We identiﬁed key knowledge gaps and suggested
directions for future research.
Conclusion
We present a guideline for the prevention and treatment of CDI in children and adolescents with
cancer and pediatric HSCT patients. Future research should include randomized controlled trials that
involve children with cancer and pediatric HSCT patients to improve the management of CDI in this
population.
J Clin Oncol 36:3162-3171. © 2018 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Clostridium difﬁcile can be a common commensal
of the normal GI ﬂora; however, isolates that
produce toxin can result in symptomatic in-
fection.1 Well-described risk factors2,3 for C. dif-
ﬁcile infection (CDI) include recent antibiotic and
chemotherapy exposure4-6 and prolonged hospi-
talization.5 As these factors are common in chil-
dren and adolescents with cancer and pediatric
hematopoietic stem-cell transplantation (HSCT)
patients, it is not surprising that CDI has emerged
as an important health care–associated infection in
this population.7
Rates of CDI are increasing over time in adults
and children,8,9 and CDI is now the most common
cause of health care–associated infectious diarrhea.10
The importance of CDI has also been highlighted
with the emergence of North American pulsed-ﬁeld
gel electrophoresis type 1, a more virulent strain
associated with higher morbidity and mortality.11 In
pediatric patients with cancer, CDI has been asso-
ciated with an increased risk of death.3
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Given the prevalence, morbidity, and mortality associated with
CDI, strategies for prevention and treatment are important. There
are several guidelines for CDImanagement that have been developed
but none is focused on pediatric patients with cancer and HSCT
patients.12-14 Our objective was to create a clinical practice guideline
(CPG) for the prevention and treatment of CDI in children and
adolescents with cancer and pediatric HSCT patients.
METHODS
The guideline panel was multidisciplinary and multinational, with rep-
resentation from pediatric oncology, pediatric infectious diseases, nursing,
pharmacy, a patient advocate, and a guideline methodologist (Data Sup-
plement). Panel members were primarily chosen on the basis of relevant
publications while considering geographic representation. We followed
standard procedures for creating evidence-based CPGs.15 No panel member
had conﬂicts of interest that precluded participation in this panel (Data
Supplement). The guideline was funded by the Pediatric Oncology Group of
Ontario. CPG creation was editorially independent from the funder.
The key clinical question addressed by the CPG was, “What in-
terventions should be administered for the prevention and treatment of
CDI in children and adolescents with cancer or pediatric HSCT patients?”
Recommendations are intended for children and adolescents up to age
18 years with cancer or undergoing HSCT. Target users of this CPG are
pediatric oncology and HSCT physicians; pediatric infectious diseases
physicians; other physicians who facilitate care for these patients, such as
general pediatric, emergency room, and intensive care unit clinicians and
hospitalists; nurse practitioners; nurses; pharmacists; and other health care
professionals who manage CDI in this population.
We used the Grading of Recommendations Assessment, Develop-
ment and Evaluation approach to generate recommendations and assign
level of evidence.16 Using the Grading of Recommendations Assessment,
Development and Evaluation approach, recommendations may be strong or
weak. With strong recommendations, beneﬁts clearly outweigh the risks or
vice versa. In this case, almost all patients should receive—or not receive—
the recommended intervention as a matter of policy. With weak recom-
mendations, the beneﬁts and risks of the intervention are uncertain or are
closely matched. In this case, preferences and values will affect intervention
administration. In addition to comparative data, we also considered costs,
resources, and logistical challenges in formulating recommendations.
The panel was aware that there are few randomized trials conducted
in any pediatric population and, in particular, children with cancer and
pediatric HSCT patients. Therefore, the published evidence considered for
this CPG included randomized controlled trials in both adults and chil-
dren, regardless of underlying condition. Only randomized data were
included because observational data may be more susceptible to bias.
When weighing the evidence, the panel considered the directness of the
data to children in general and to children with severe neutropenia and
immune suppression as a result of cancer treatment in particular. If
recommendations relied on adult trials or immunocompetent patients,
evidence quality was downgraded because of indirectness.
With the assistance of a library scientist, we searched for randomized
trials indexed from 1980 to March 15, 2018, in the following databases:
Medline, Medline in-process, Embase, and the Cochrane Central Register
of Controlled Trials. Full search strategies are available in the Data
Supplement.
Eligibility criteria were deﬁned a priori. We included studies if pa-
tients were human participants, it was a fully published randomized trial
with a parallel group design, and it evaluated an intervention for the
prevention or treatment of CDI. Exclusion criteria were, for prevention
interventions, CDI was not a study end point or was reported as an adverse
event; and for treatment interventions, the study population was com-
prised of less than 90% of patients who were determined to have C. difﬁcile
as a cause of diarrhea. Studies published in any language were evaluated.
Screening of titles and abstracts, review of full articles for eligibility,
and data abstraction were performed independently by two investigators
(C.D. and P.D.R.). Any disagreements were resolved by a third reviewer
(L.S.). Agreement on study inclusion between reviewers was evaluated
using the k statistic. Strength of agreement was deﬁned as slight (0.00 to
0.20), fair (0.21 to 0.40), moderate (0.41 to 0.60), substantial (0.61 to 0.80),
or almost perfect (0.81 to 1.00).17
Interventions were divided into those for the prevention and those for
the treatment of CDI. For prevention studies, the primary outcome was CDI
as deﬁned by the presence of diarrhea and ameasure ofC. difﬁcile toxin from
stool. Adverse events were also considered. For treatment studies, outcomes
were cure at the end of the treatment period, cure at the end of the follow-up
period, recurrence, and adverse events. In studies with more than two arms,
the most commonly studied intervention was compared with placebo, no
therapy, or standard of care. If none of these was present, then the least-
intensive treatment was selected as the control arm. In the event that more
than one intervention was evaluated at a similar frequency in these mul-
tiarmed trials, the one considered by the panel to be the most active was
selected as the intervention arm before seeing the data.
Given the potential for adverse infectious events associated with
probiotic or prebiotic administration, we also conducted a separate sys-
tematic review to describe invasive infection associated with adminis-
tration in children with cancer and pediatric HSCT patients. The complete
search strategy is provided in the Data Supplement. The same general
procedures were followed as described previously. Eligibility criteria were
as follows: participants were age , 25 years with cancer or undergoing
HSCT (threshold related to age categorization in the search databases),
there was exposure to a probiotic or prebiotic agent, and adverse events
were reported. Outcomes for this analysis were reported infections and
whether the study authors’ attribution of the infection to the probiotic or
prebiotic was deemed likely or unlikely.
For randomized trial systematic reviews, synthesis was performed
when there were at least three studies within a subgroup. Effects were
presented as the risk ratio (RR) and the corresponding 95%CIs. Effect sizes
were weighted by the Mantel-Haenszel method, and a random effects
model was used for all analyses as we anticipated heterogeneity in effects.
Meta-analyses were conducted using Review Manager 5.3 (Cochrane
Collaboration, Nordic Cochrane Centre). All tests of signiﬁcance were two
sided, and statistical signiﬁcance was deﬁned as P , .05.
We evaluated the risk of bias using the Cochrane Collaboration’s tool
for assessing bias in randomized trials.18 Publication bias was explored by
visual inspection of funnel plots when at least 10 studies were available for
synthesis.18
We created evidence tables using synthesized results. Tables were
reviewed and recommendations debated in a series of conference calls.
Iterations of the ﬁnal CPG were circulated until all authors agreed with its
content. A ﬁnal revised version was not sent to external experts before
submission for publication as the guideline panel contained considerable
expertise in pediatric CDI. Instead, we used the peer-review process during
manuscript submission as a rigorous and efﬁcient approach to external
review. A guideline update is planned in 5 years or sooner in the event of
the publication of important new information.
EVIDENCE BASE, RECOMMENDATIONS, AND EXPLANATIONS
Overall, 63 publications—reporting 65 randomized studies—met
the eligibility criteria and provided the main evidence base for this
CPG. Figure 1 illustrates the ﬂow diagram of study identiﬁcation
and selection. Agreement in study inclusion between reviewers was
almost perfect (k = 0.96; 95% CI, 0.91 to 1.00). Table 1 lists the
characteristics of included trials stratiﬁed by prevention or
treatment studies and by the speciﬁc intervention group. Addi-
tional details of the included studies are provided in the Data
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Supplement. All 18 prevention trials evaluated probiotics or
prebiotics. There were 47 treatment trials, of which 45 were in
a category amenable to synthesis, namely antibiotics, fecal microbiota
transfer (FMT), monoclonal antibodies, and probiotics or pre-
biotics. Funnel plots did not suggest evidence of publication bias
(data not shown). Table 2 lists health questions, recommendations,
and remarks in addition to strength of recommendation and level
of evidence. Knowledge gaps are listed in Table 3.
Recommendation 1
We suggest that probiotics not be used routinely for the
prevention of CDI in children and adolescents with cancer and
pediatric HSCT patients. (Weak recommendation, low-quality
evidence.)
Literature Review and Analysis
Eighteen studies were included in the analysis of probiotics or
prebiotics for the prevention of CDI, with 17 studies of probiotic
agents and one study of a prebiotic agent (oligofructose) (Data
Supplement). All studies administered probiotics as primary pro-
phylaxis. The most common probiotics studied were Lactobacillus
acidophilus (n = 7 trials), Saccharomyces boulardii (n = 5 trials), and
Lactobacillus rhamnosus (n = 2 trials). None of the studies included
immunocompromised children, and only 22 immunocompromised
adults were known to be included across all studies.
When all 18 studies were synthesized, probiotics or prebiotics
reduced the risk of CDI (RR, 0.44; 95% CI, 0.28 to 0.70; Table 4).
Similar effects were observed when studies were restricted to
placebo-controlled trials, probiotic versus placebo trials, and pe-
diatric probiotic versus placebo trials (Table 4). When stratiﬁed
by probiotic type, signiﬁcant heterogeneity was not observed
(Pinteraction = .37). Table 5 lists the results of the systematic review to
assess the safety of probiotic or prebiotic agents in pediatric pa-
tients with cancer or HSCT patients. There were three cases of
invasive infection attributed by the study authors to a probiotic,
namely Lactobacillus bacteremia,21 absidiomycosis,24 and Saccha-
romyces fungemia.25
The panel valued the rare but observed attribution of invasive
infection to either a probiotic itself or contamination of the
probiotic in pediatric patients with cancer. Although the beneﬁts of
probiotics were observed in trials primarily composed of immu-
nocompetent adults, the panel was concerned about generaliz-
ability to pediatric immunocompromised patients. Evidence was
Citations screened by
title/abstract
(n = 6,489)
Duplicates removed
(n = 2,157)
Citations excluded as did
not meet eligibility criteria
(n = 6,255)
Full-text papers retrieved for
detailed evaluation
(n = 234)
Excluded
  Not fully published
  Not parallel group RCT
  Not intervention for CDI prevention or treatment
  CDI not study end-point or adverse event
  < 90% had CDI in treatment study
  Duplicate
  Not retrievable
(n = 171)
(n = 17)
(n = 30)
(n = 74)
(n = 25)
(n = 3)
(n = 11)
(n = 11)
Potentially relevant
references identified
(N = 8,646) 
Included papers
(n = 63;
reporting 65 randomized studies)
Fig 1. Flow diagram depicting study identiﬁcation, selection,
and reasons for exclusion.
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considered low quality because the lack of data in neutropenic
children with cancer or HSCT recipients resulted in an inability of
panel members to conclude that the beneﬁts of probiotics would
outweigh safety concerns in our patient population. In particular,
the need for an intervention to prevent CDI is greater during
profound and prolonged neutropenia when antibiotic exposure
and hospitalization are frequent. However, this period may be
contemporaneous with a higher risk of developing invasive in-
fection from probiotics. Thus, probiotic administration in pedi-
atric patients with cancer and HSCT patients for primary or
secondary prophylaxis of CDI should be restricted to the research
setting, particularly in severely neutropenic patients. If a probiotic
is administered, a formulation certiﬁed as being free of bacterial
and fungal contamination is preferred.
Recommendation 2
Use either oral metronidazole or oral vancomycin for the
treatment of nonsevere CDI in children and adolescents with
cancer and pediatric HSCT patients. (Strong recommendation,
low-quality evidence.)
Literature Review and Analysis
Among the 29 publications that compared different antibi-
otics for the treatment of CDI, there were three comparisons with
synthesizable data, namely vancomycin versus metronidazole,
ﬁdaxomicin versus vancomycin, and surotomycin versus vanco-
mycin (Data Supplement). Fidaxomicin versus vancomycin will be
addressed with Recommendation 4.
We identiﬁed ﬁve trials that compared vancomycin with
metronidazole26-29 (Table 4 and Data Supplement). None of these
studies included children and only two studies included 65 patients
with cancer. When these studies were synthesized, vancomycin was
not associated with better cure rates at the end of the antibiotic
treatment (RR, 1.05; 95% CI, 1.00 to 1.11), cure at the end of the
follow-up period (RR, 1.07; 95% CI, 0.97 to 1.19), or recurrence
risk (RR, 0.89; 95% CI, 0.65 to 1.23).
Among the three studies that compared surotomycin with
vancomycin, there were no signiﬁcant differences in cure at the end
of the antibiotic treatment (RR, 0.98; 95% CI, 0.93 to 1.03), cure at
the end of the follow-up period (RR, 1.06; 95% CI, 0.96 to 1.17), or
recurrence risk (RR, 0.80; 95% CI, 0.62 to 1.03).30-32
The panel valued the similar cure and recurrence rates of
metronidazole compared with vancomycin among all analyzed
patients in making a strong recommendation that either agent be
used for the initial treatment of nonsevere CDI in children with
cancer or pediatric HSCT recipients. Better palatability favors oral
vancomycin, whereas oral metronidazole may be more cost ef-
fective.33 An additional consideration is the potential for drug–
drug interactions with metronidazole. Oral vancomycin, which is
not systemically absorbed, is favored in patients with CDI who
receive concomitant medications known or suspected to interact
with metronidazole. The panel assigned low-quality evidence
because of the absence of direct evidence comparing vancomycin
with metronidazole in children with cancer and pediatric HSCT
patients. Surotomycin was not included as an option for the initial
treatment of CDI because it was not better than vancomycin, there
are limited data in pediatric populations, and it is not routinely
available for clinical use. Determining the beneﬁts and risks of
different antibiotic treatment approaches, particularly among
those who cannot tolerate oral antibiotic administration, is an
important knowledge gap (Table 3).
Table 1. Characteristics of Included Randomized Trials by Intervention Group
Characteristic
All Studies
(N = 65)
Prevention Treatment
Probiotics and Prebiotics
(n = 18)
Antibiotics
(n = 29)
FMT
(n = 9)
Monoclonal Antibodies
(n = 4)
Probiotics and Prebiotics
(n = 3)
Other
(n = 2)
Study population
Adult 56 (86) 13 (72) 26 (90) 8 (89) 4 (100) 3 (100) 2 (100)
Pediatric 6 (9) 5 (28) 1 (3) 0 (0) 0 (0) 0 (0) 0 (0)
Both 3 (5) 0 (0) 2 (7) 1 (11) 0 (0) 0 (0) 0 (0)
Immune status
Immunocompetent only 23 (35) 13 (72) 2 (7) 5 (56) 0 (0) 2 (67) 1 (50)
Immunocompromised included 14 (22) 2 (11) 7 (24) 2 (22) 2 (50) 1 (33) 0 (0)
Not reported 28 (43) 3 (17) 20 (69) 2 (22) 2 (50) 0 (0) 1 (50)
Patients with cancer included 13 (20) 2 (11) 7 (24) 1 (11) 2 (50) 1 (33) 0 (0)
HSCT recipients included 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Control group type
Placebo 26 (40) 16 (89) 1 (3) 0 (0) 4 (100) 3 (100) 2 (100)
Usual care 2 (3) 2 (11) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other intervention 37 (57) 0 (0) 28 (97) 9 (100) 0 (0) 0 (0) 0 (0)
Risk of bias adequacy*
Sequence generation 32 (49) 11 (61) 13 (45) 6 (67) 0 (0) 1 (33) 1 (50)
Allocation concealment 31 (48) 12 (67) 14 (48) 3 (33) 0 (0) 1 (33) 1 (50)
Participants blinded 44 (68) 16 (89) 16 (55) 3 (33) 4 (100) 3 (100) 2 (100)
Outcome assessors blinded 36 (55) 12 (67) 15 (52) 3 (33) 4 (100) 2 (67) 0 (0)
Lack of attrition bias 52 (80) 11 (61) 26 (90) 9 (100) 3 (75) 1 (33) 2 (100)
Free of selective reporting 47 (72) 8 (44) 23 (79) 9 (100) 2 (50) 3 (100) 2 (100)
NOTE. Data are given as No. (%).
Abbreviations: FMT, fecal microbiota transplantation; HSCT, hematopoietic stem-cell transplantation.
*Number of studies adjudicated to have these attributes and thus at reduced risk of bias.
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This recommendation is focused on children with nonsevere
CDI. Unfortunately, deﬁnitions for nonsevere and severe CDI have
not been established in pediatric oncology. Whereas a deﬁnition for
severe CDI has been proposed for adult patients, the panel cautions
against the generalization of this deﬁnition to children with cancer as
the adult deﬁnition includes parameters, such as higher WBC count
and age . 60 years (Data Supplement). On the basis of clinical
experience, the panel suggests that severe CDI in pediatric oncology
could be deﬁned provisionally as CDI in the presence of toxic
megacolon, pseudomembranous colitis, or hemodynamic instability.
However, the lack of a robust deﬁnition of severe CDI in pediatric
cancer and HSCT populations is an important research gap (Table 3).
Table 2. Summary of CDI Prevention and Treatment Recommendations for Children With Cancer and Pediatric HSCT Patients
Health Question and Recommendation
Strength of Recommendation and
Level of Evidence
Question:What interventions should be used for the prevention of CDI in children and adolescents with cancer
and pediatric HSCT patients?
Recommendation 1: We suggest that probiotics not be used routinely for the prevention of CDI in children
and adolescents with cancer and pediatric HSCT patients
Weak recommendation
Remarks: The panel valued the rare but observed attribution of invasive infection to either a probiotic itself
or contamination of the probiotic in pediatric patients with cancer. Although beneﬁts of probiotics were
observed in trials that were primarily composed of immunocompetent adults, the panel was concerned
about generalizability to pediatric immunocompromised patients. Thus, probiotic administration in
pediatric patients with cancer and HSCT patients should be restricted to the research setting, particularly
in severely neutropenic patients.
Low-quality evidence
Question:What interventions should be used for the treatment of CDI in children and adolescents with cancer
and pediatric HSCT patients?
Recommendation 2: Use either oral metronidazole or oral vancomycin for the treatment of nonsevere CDI in
children and adolescents with cancer and pediatric HSCT patients
Strong recommendation
Remarks: The panel valued the similar cure and recurrence rates of metronidazole compared with
vancomycin among all analyzed patients. Although either may be used, better palatability favors oral
vancomycin, whereas oral metronidazole may be more cost effective.
Low-quality evidence
Recommendation 3: Use oral vancomycin for the treatment of severe CDI in children and adolescents with
cancer and pediatric HSCT patients
Strong recommendation
Remarks: The panel considered the better efﬁcacy of vancomycin in achieving cure at the end of antibiotic
treatment of those patients with severe disease among adults. Unfortunately, there are no pediatric
deﬁnitions for severe CDI and the adult criteria for severe disease cannot be extended to children with
cancer. Indirectness both in terms of being able to deﬁne severe CDI and applying efﬁcacy results to
children who receive cancer treatment led to the designation of low-quality evidence. However, the
panel concluded that the potential for improved efﬁcacy and likely better tolerability favored vancomycin
as initial therapy in children with cancer who were severely ill from CDI. A deﬁnition of severe disease in
this population is lacking and is an important research gap.
Low-quality evidence
Recommendation 4: Consider ﬁdaxomicin for the treatment of recurrent CDI in children and adolescents with
cancer and pediatric HSCT patients
Weak recommendation
Remarks: The panel considered the better efﬁcacy of ﬁdaxomicin compared with vancomycin in achieving
cure at the end of the follow-up period and in reducing CDI recurrence in adults. These results were
balanced against the lack of data for ﬁdaxomicin in children, including children who receive cancer
treatments. Absence of direct data resulted in uncertainty about the relative effects of ﬁdaxomicin in our
target population and, consequently, the designation of low-quality evidence. Other factors considered
were the substantial costs of the drug, uncertainty regarding optimal dosing, and limited experience in
children. Given these factors, ﬁdaxomicin was not included as an option for the initial treatment of CDI;
however, it may be considered in the setting of recurrent CDI.
Low-quality evidence
Recommendation 5: Do not use fecal microbiota transplantation routinely for the treatment of CDI in children
and adolescents with cancer and pediatric HSCT patients
Strong recommendation
Remarks: The panel recognized the considerable uncertainty regarding the efﬁcacy of fecal microbiota
transplantation comparedwith vancomycin in the three randomized trials. The substantial indirectness of
the supporting evidence as a result of the virtual absence of randomized data in any patient with
neutropenia because of cancer therapies and in childrenwho receive cancer treatments, including HSCT,
led to the designation of low-quality evidence. When these issues were combined with challenges
related to the mode of administration—for example, colonoscopy and need for bowel preparation—the
panel made a strong recommendation against the routine use of fecal transplants. However, pediatric
patients with cancer should be included in future research that evaluates fecal transplantation for the
treatment of CDI.
Low-quality evidence
Recommendation 6:We suggest that monoclonal antibodies not be used routinely for the treatment of CDI in
children and adolescents with cancer and pediatric HSCT patients
Weak recommendation
Remarks: The panel valued the absence of randomized data in any pediatric patient and in patients who
were known to be immunocompromised as a result of cancer chemotherapy as well as the potential for
harm. Although the panel acknowledged the efﬁcacy of combination actoxumab and bezlotoxumab in
reducing the risk of recurrent CDI, the lack of direct efﬁcacy and safety data, uncertainty in pediatric
dosing, and substantial costs led to the weak recommendation against their routine use.
Low-quality evidence
Recommendation 7:We suggest that probiotics not be used routinely for the treatment of CDI in children and
adolescents with cancer and pediatric HSCT patients.
Weak recommendation
Remarks: The panel weighed the potential efﬁcacy of these agents to reduce CDI recurrence against the
potential for invasive infection raised in Recommendation 1. Given the lack of direct efﬁcacy and safety
data in children with cancer and pediatric HSCT patients, the panel made a weak recommendation
against the routine use of probiotics to treat CDI.
Low-quality evidence
Abbreviations: CDI, Clostridium difficile infection; HSCT, hematopoietic stem-cell transplantation.
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Recommendation 3
Use oral vancomycin for the treatment of severe CDI in
children and adolescents with cancer and pediatric HSCT patients.
(Strong recommendation, low-quality evidence.)
Literature Review and Analysis
Three of the vancomycin versus metronidazole studies re-
ported outcomes for a subset of patients with severe CDI26,27
(Table 4 and Data Supplement). Vancomycin was associated with
a signiﬁcantly higher cure rate at the end of the antibiotic treatment
compared with metronidazole among patients with severe CDI
(RR, 1.22; 95% CI, 1.05 to 1.42).
The panel considered the better efﬁcacy of vancomycin in
achieving cure at the end of the antibiotic treatment of those
patients with severe disease among adults. Indirectness both in
terms of being able to deﬁne severe CDI and applying efﬁcacy
results to our population led to the designation of low-quality
Table 3. Key Knowledge Gaps
Knowledge Gap
Among children and adolescents with cancer and pediatric HSCT patients:
Describe the risk of recurrence among those with CDI
Establish a deﬁnition of severe CDI
Determine the beneﬁts and risks of different prophylactic and therapeutic strategies speciﬁcally in this population
Identify treatment strategies for those who cannot tolerate oral antibiotics
Determine the safety of probiotics and fecal microbial transplantation in this population, particularly among those with severe neutropenia and severe
immunosuppression
Determine the optimal treatment of severe, refractory, and recurrent CDI
Determine the cost effectiveness of ﬁdaxomicin v metronidazole and vancomycin for the treatment of initial and recurrent CDI
Abbreviations: CDI, Clostridium difficile infection; HSCT, hematopoietic stem-cell transplantation.
Table 4. Efﬁcacy of Interventions for the Prevention and Treatment of CDI
Outcome No. of Studies No. of Patients RR 95% CI I2 (%) P
Interventions for prevention of CDI
Probiotics or prebiotics
Probiotic or prebiotic v any control 18 6,464 0.44 0.28 to 0.70 27 , .001
Probiotic or prebiotic v placebo 16 6,023 0.47 0.29 to 0.75 29 .002
Probiotic v placebo* 15 5,588 0.41 0.25 to 0.66 14 , .001
Lactobacillus acidophilus v placebo 7 3,941 0.31 0.14 to 0.72 41 .006
Saccharomyces boulardii v placebo 4 1,078 0.55 0.23 to 1.31 0 .18
Pediatric probiotic v placebo 4 702 0.40 0.17 to 0.96 0 .04
Interventions for treatment of CDI
Antibiotics
Vancomycin v metronidazole (all)
Cure at the end of antibiotic treatment 5 856 1.05 1.00 to 1.11 0 .07
Cure at the end of follow-up 5 856 1.07 0.97 to 1.19 33 .19
Recurrence 5 705 0.89 0.65 to 1.23 0 .48
Vancomycin v metronidazole (severe)
Cure at the end of antibiotic treatment 3 234 1.22 1.05 to 1.42 0 .01
Recurrence 3 176 0.95 0.37 to 2.34 50 .91
Fidaxomicin v vancomycin
Cure at the end of antibiotic treatment 4 1,491 1.01 0.96 to 1.06 22 .28
Cure at the end of follow-up 4 1,489 1.19 1.11 to 1.27 0 , .001
Recurrence 4 1,272 0.49 0.34 to 0.71 41 , .001
Surotomycin v vancomycin
Cure at the end of antibiotic treatment 3 1,280 0.98 0.93 to 1.03 0 .41
Cure at the end of follow-up 3 1,280 1.06 0.96 to 1.17 17 .28
Recurrence 3 1,056 0.80 0.62 to 1.03 25 .09
Fecal microbiota transfer
Fresh v vancomycin 3 ND†
Monoclonal antibodies
Actoxumab plus bezlotuxumab v placebo
Recurrence 3 1,389 0.57 0.42 to 0.77 51 , .001
Probiotics or prebiotics
Probiotic or prebiotic v placebo
Recurrence 3 278 0.46 0.27 to 0.77 38 .004
Abbreviations: CDI, Clostridium difficile infection; ND, not done; RR, risk ratio.
*P for interaction when evaluating probiotic type = .37.
†Not done because studies were too heterogeneous to synthesize.
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evidence. Nonetheless, the panel concluded that the potential for
improved efﬁcacy and likely better tolerability favored vancomycin
as the initial therapy in pediatric patients with cancer who were
severely ill from CDI.
Recommendation 4
Consider ﬁdaxomicin for the treatment of recurrent CDI in
children and adolescents with cancer and pediatric HSCT patients.
(Weak recommendation, low-quality of evidence.)
Literature Review and Analysis
We identiﬁed ﬁve randomized controlled trials that evaluated
ﬁdaxomicin. We synthesized four trials that compared ﬁdaxomicin
with vancomycin34-37 (Table 4 and Data Supplement). None of the
studies included children and one study included 75 adult patients
with cancer. Whereas ﬁdaxomicin did not result in a higher cure
rate at the end of the antibiotic treatment (RR, 1.01; 95% CI, 0.96
to 1.06), ﬁdaxomicin was signiﬁcantly better than vancomycin in
achieving cure at the end of the follow-up period (RR, 1.19; 95%
CI, 1.11 to 1.27) and reducing the risk of recurrence (RR, 0.49; 95%
CI, 0.34 to 0.71).
The panel considered the better efﬁcacy of ﬁdaxomicin
compared with vancomycin in achieving cure at the end of the
follow-up period and in reducing CDI recurrence in adults. These
results were balanced against the lack of data for ﬁdaxomicin in
children, including in children who receive cancer treatments.
Absence of direct data resulted in uncertainty about the relative
effects of ﬁdaxomicin in our target population and, consequently,
the designation of low-quality evidence. Other factors considered
were the substantial costs of the drug, uncertainty regarding op-
timal dosing, and limited experience in children. Given these
factors, ﬁdaxomicin was not included as an option for the initial
treatment of CDI; however, it may be considered in the setting of
recurrent CDI.
Efﬁcacy of ﬁdaxomicin over vancomycin was demonstrated in
reducing the risk of recurrence in patients with CDI. Risk of re-
currence in pediatric patients with cancer and HSCT patients who
experience CDI is uncertain and was identiﬁed as an important
knowledge gap. Future research should also evaluate the cost ef-
fectiveness of ﬁdaxomicin compared with metronidazole and
vancomycin for initial and recurrent CDI (Table 3).
Recommendation 5
Do not use FMTroutinely for the treatment of CDI in children
and adolescents with cancer and pediatric HSCT patients. (Strong
recommendation, low-quality evidence.)
Literature Review and Analysis
There were nine randomized trials of FMT, of which eight
included adults only and one that included both adults and
children (Data Supplement). The eight adult trials included a total
of seven patients with cancer. The one mixed-age trial included
only three children and speciﬁcally excluded patients receiving
chemotherapy.
These trials used heterogeneous approaches to FMT (fresh
and frozen) and different control arms (vancomycin and different
types of FMT). Among these studies, the only common approach
was fresh FMT versus vancomycin in three studies. These three
trials yielded different results,38-40 with two being stopped early for
efﬁcacy38,40 and one for futility39 (Data Supplement). There was
substantial heterogeneity related to the route of fecal transplant
administration, pretransplant therapies (duration of vancomycin
and requirement for bowel preparation), and control arms (du-
ration of vancomycin). These issues precluded synthesis (Data
Supplement).
The panel recognized the considerable uncertainty with regard
to the efﬁcacy of FMT compared with vancomycin in the three
randomized trials. The substantial indirectness of the supporting
Table 5. Safety of Probiotics or Prebiotics in Children With Cancer and Pediatric HSCT Patients
Author Year Study Design
Age
Range,
Years Population Cancer Therapy
Probiotic or
Prebiotic
Intervention
Attribution to
Probiotic or
Prebiotic
CommentsLikely
Not
Likely
Du et al19 2018 Intervention arm,
nonrandomized trial
1-14 Cancer Radiation Bacillus
licheniformis
0/80 0/80 No chemotherapy
Ladas et al20 2016 Prospective single-
arm study
2-17 HSCT Allogeneic
HSCT
Lactobacillus
plantarum
0/30 6/30 Probiotic certiﬁed free of bacterial
and fungal contamination
Lee and Siao-
Ping Ong21
2011 Case report 2 Cancer None (at
diagnosis of
ALL)
Speciﬁc probiotic
not reported
1/1 0/1 Lactobacillus bacteremia
“suspected to be of probiotic
origin”
Wada et al22 2010 Intervention arm,
randomized trial
1-13 Cancer Chemotherapy Bifidobacterium
breve
0/18 2/18 Pseudomonas aeruginosa and
Staphylococcus bacteremia
Zheng et al23 2006 Intervention arm,
randomized trial
1-12 Cancer Chemotherapy Fructo-
oligosaccharide
formula
0 /31 0/31
Bellete et al24 2006 Case report 10 Cancer Chemotherapy Colotium capsules 1/1 0/1 Intestinal absidiomycosis; same
genus found in the probiotic
Cesaro et al25 2000 Case report 0.7 Cancer Chemotherapy Saccharomyces
boulardii
1/1 0/1 Saccharomyces cerevisiae fungemia
considered related to the probiotic
as a result of species similarity and
rarity of infection
Abbreviations: ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem-cell transplantation.
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evidence as a result of the virtual absence of randomized data in
any patient with neutropenia because of cancer therapies and in
children receiving cancer treatments, including HSCT, led to the
designation of low-quality evidence. When these issues were com-
bined with challenges related to the mode of administration—
for example, colonoscopy and need for bowel preparation—the
panel made a strong recommendation against the routine use of
FMT. However, pediatric patients with cancer should be in-
cluded in future research that evaluates FMT for the treatment
of CDI.
Recommendation 6
We suggest that monoclonal antibodies not be used routinely
for the treatment of CDI in children and adolescents with cancer
and pediatric HSCT patients. (Weak recommendation, low-quality
evidence.)
Literature Review and Analysis
Four randomized controlled trials of monoclonal antibodies
for the treatment of CDI were identiﬁed.41-43 There were no
children included in any of these studies, and although two
studies included immunocompromised patients, the number
who received cancer therapies was not reported.41 Three studies
that compared a combination of actoxumab and bezlotoxumab
with placebo were synthesized. In all three studies, monoclonal
antibodies were used as an adjuvant to standard antibiotics,
namely vancomycin, metronidazole, or ﬁdaxomicin (Data Sup-
plement). Administration of actoxumab plus bezlotoxumab
signiﬁcantly reduced the risk of CDI recurrence (RR, 0.57; 95% CI,
0.42 to 0.77).
The panel valued the absence of randomized data in any
pediatric patient or in patients who were known to be im-
munocompromised as a result of cancer chemotherapy. They
also considered the potential for harm given the systemic
administration of these agents. Although the panel acknowl-
edged the efﬁcacy of combination actoxumab and bezlotox-
umab in reducing the risk of recurrent CDI, the lack of direct
efﬁcacy and safety data, uncertainty in pediatric dosing, and
substantial costs led to the weak recommendation against their
routine use.
We made an a priori decision as outlined in our methods to
evaluate the combination of actoxumab and bezlotoxumab as it
was the most commonly studied monoclonal antibody in-
tervention among interventions included in multiarmed trials.
However, only bezlotoxumab, and not the combination of
actoxumab and bezlotoxumab, is approved by the US Food and
Drug Administration48 and the European Medicines Agency,49
and thus, evaluation of bezlotoxumab alone is of interest. As
there were only two studies41 available that evaluated bezlo-
toxumab alone, we could not conduct synthesis.
Recommendation 7
We suggest that probiotics not be used routinely for the
treatment of CDI in children and adolescents with cancer and
pediatric HSCT patients. (Weak recommendation, low-quality
evidence.)
Literature Review and Analysis
This recommendation refers to the administration of a pro-
biotic during a CDI episode as an adjunct to CDI-directed anti-
biotic therapy, not as secondary prophylaxis. Three trials examined
probiotics or prebiotics for the treatment of CDI (Data Supple-
ment).44-46 No children were included in any of these studies, and
only one patient with cancer was included. All studies compared
the intervention with placebo when used as an adjuvant to
standard antibiotic therapy for CDI. Probiotics or prebiotics
signiﬁcantly reduced CDI recurrence (RR, 0.46; 95% CI, 0.27 to
0.77).
The panel weighed the potential efﬁcacy of these agents to
reduce CDI recurrence against the potential for invasive infection
raised in Recommendation 1. Given the lack of direct efﬁcacy and
safety data in childrenwith cancer and pediatric HSCT patients, the
panel made a weak recommendation against the routine use of
probiotics to treat CDI.
DISCUSSION
In this CPG guided by an international multidisciplinary panel,
we present recommendations for the prevention and treatment
of CDI in children with cancer and pediatric HSCT patients. The
panel made strong recommendations to use either oral met-
ronidazole or oral vancomycin for the initial treatment of
nonsevere CDI and oral vancomycin for the initial treatment of
severe CDI. Fidaxomicin may be considered in the setting of re-
current CDI. The panel suggested that probiotics not be rou-
tinely used for the prevention of CDI and that monoclonal
antibodies and probiotics not be routinely used for the treatment
of CDI. A strong recommendation to not use FMTwas made for
this population.
A striking ﬁnding across the evidence informing this CPG is
the lack of high-quality evidence as a result of the omission of
pediatric patients with cancer and HSCT patients from ran-
domized trials. Thus, future trials should either focus on this
population exclusively or include these pediatric patients in adult
trials. Direct data are important. Children who receive cancer
therapies will differ from adults with cancer and immunocom-
petent children in terms of antibiotic exposure, concomitant
medications, and comorbidities.47 Of importance, children with
cancer frequently receive intensive myelosuppressive chemother-
apy and most pediatric HSCT procedures are myeloablative. Thus,
the safety of any intervention, particularly as it relates to live
products, such as probiotics and some FMT procedures, are im-
portant to evaluate directly before recommending their routine use.
Some knowledge gaps can be addressed with observational
studies and include describing the recurrence rate of CDI and
deﬁning and describing those with severe disease in this pop-
ulation. Such studies should be multicenter with large sample sizes
to ensure generalizability and precision in estimates. In our review,
we found that CDI treatment trials typically reported multiple end
points, including cure at the end of the antibiotic treatment period,
cure at the end of the follow-up period, and recurrence. The
relative importance of these end points is not established and
stakeholders may value them differently.
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In summary, we present a guideline for the prevention and
treatment of CDI in children and adolescents with cancer and pediatric
HSCT patients. Future research should deﬁne severe CDI and conduct
randomized trials that include children with cancer and pediatric
HSCT patients to improve themanagement of CDI in this population.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Disclosures provided by the authors are available with this article at
jco.org.
AUTHOR CONTRIBUTIONS
Conception and design: Caroline Diorio, Paula D. Robinson,
Elio Castagnola, Brian T. Fisher, Robert Phillips, L. Lee Dupuis,
Lillian Sung
Administrative support: Sandra Cabral
Collection and assembly of data: Caroline Diorio, Paula D. Robinson,
Sandra Cabral, Lillian Sung
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
REFERENCES
1. Kelly CP, Pothoulakis C, LaMont JT: Clostrid-
ium difficile colitis. N Engl J Med 330:257-262, 1994
2. Kim J, Shaklee JF, Smathers S, et al: Risk
factors and outcomes associated with severe Clos-
tridium difficile infection in children. Pediatr Infect Dis
J 31:134-138, 2012
3. de Blank P, Zaoutis T, Fisher B, et al: Trends in
Clostridium difficile infection and risk factors for
hospital acquisition of Clostridium difficile among
children with cancer. J Pediatr 163:699-705.e1, 2013
4. Gerding DN, Johnson S, Peterson LR, et al:
Clostridium difficile-associated diarrhea and colitis.
Infect Control Hosp Epidemiol 16:459-477, 1995
5. Palmore TN, Sohn S, Malak SF, et al: Risk
factors for acquisition ofClostridium difficile-associated
diarrhea among outpatients at a cancer hospital. Infect
Control Hosp Epidemiol 26:680-684, 2005
6. Anand A, Glatt AE: Clostridium difficile in-
fection associated with antineoplastic chemother-
apy: A review. Clin Infect Dis 17:109-113, 1993
7. Sammons JS, Toltzis P, Zaoutis TE: Clostrid-
ium difficile Infection in children. JAMA Pediatr 167:
567-573, 2013
8. Chen Y, Glass K, Liu B, et al: A population-
based longitudinal study of Clostridium difficile
infection-related hospitalization in mid-age and older
Australians. Epidemiol Infect 145:575-582, 2017
9. Pant C, Deshpande A, Gilroy R, et al: Rising
incidence of Clostridium difficile related discharges
among hospitalized children in the United States.
Infect Control Hosp Epidemiol 37:104-106, 2016
10. McDonald LC, Killgore GE, Thompson A, et al:
An epidemic, toxin gene-variant strain of Clostridium
difficile. N Engl J Med 353:2433-2441, 2005
11. Khan A, Raza S, Batul SA, et al: The evolution
of Clostridium difficile infection in cancer patients:
Epidemiology, pathophysiology, and guidelines for
prevention and management. Recent Patents Anti-
Infect Drug Disc 7:157-170, 2012
12. McDonald LC, Gerding DN, Johnson S, et al:
Clinical practice guidelines for Clostridium difficile
infection in adults and children: 2017 update by the
Infectious Diseases Society of America (IDSA) and
Society for Healthcare Epidemiology of America
(SHEA). Clin Infect Dis 66:987-994, 2018
13. Trubiano JA, Cheng AC, Korman TM, et al:
Australasian Society of Infectious Diseases updated
guidelines for themanagement ofClostridium difficile
infection in adults and children in Australia and New
Zealand. Intern Med J 46:479-493, 2016
14. Schutze GE, Willoughby RE, Committee on
Infectious Diseases, et al: Clostridium difficile infection
in infants and children. Pediatrics 131:196-200, 2013
15. Oxman AD, Fretheim A, Schu¨nemann HJ:
Improving the use of research evidence in guideline
development: Introduction. Health Res Policy Syst 4:
12, 2006
16. Brozek JL, Akl EA, Alonso-Coello P, et al:
Grading quality of evidence and strength of recom-
mendations in clinical practice guidelines. Part 1 of 3.
An overview of the GRADE approach and grading
quality of evidence about interventions. Allergy 64:
669-677, 2009
17. Koch GG, Landis JR, Freeman JL, et al: A
general methodology for the analysis of experiments
with repeated measurement of categorical data.
Biometrics 33:133-158, 1977
18. Higgins JPT, Green S (eds): Cochrane Hand-
book for Systematic Reviews of Interventions Version
5.1.0. London, United Kingdom, The Cochrane Col-
laboration, 2011. http://www.cochrane-handbook.org
19. Du SX, Jia YR, Ren SQ, et al: The protective
effects of Bacillus licheniformis preparation on gas-
trointestinal disorders and inﬂammation induced by
radiotherapy in pediatric patients with central ner-
vous system tumor. Adv Med Sci 63:134-139, 2018
20. Ladas EJ, Bhatia M, Chen L, et al: The safety
and feasibility of probiotics in children and adoles-
cents undergoing hematopoietic cell transplantation.
Bone Marrow Transplant 51:262-266, 2016
21. Lee ACW, Siao-Ping Ong ND: Food-borne
bacteremic illnesses in febrile neutropenic children.
Hematol Rep 3:e11, 2011
22. Wada M, Nagata S, Saito M, et al: Effects of
the enteral administration of Bifidobacterium breve
on patients undergoing chemotherapy for pediatric
malignancies. Support Care Cancer 18:751-759,
2010 [Erratum: Support Care Cancer 18:1235-1236,
2010]
23. Zheng S, Steenhout P, Kuiran D, et al: Nutritional
support of pediatric patients with cancer consuming an
enteral formula with fructooligosaccharides. Nutr Res
26:154-162, 2006
24. Bellete B, Raberin H, Berger C, et al: Molecular
conﬁrmation of an absidiomycosis following treat-
ment with a probiotic supplement in a child with
leukemia. J Mycol Med 16:72-76, 2006
25. Cesaro S, Chinello P, Rossi L, et al: Saccha-
romyces cerevisiae fungemia in a neutropenic patient
treated with Saccharomyces boulardii. Support Care
Cancer 8:504-505, 2000
26. Johnson S, Louie TJ, Gerding DN, et al: Van-
comycin, metronidazole, or tolevamer for Clostridium
difficile infection: Results from two multinational,
randomized, controlled trials. Clin Infect Dis 59:
345-354, 2014
27. Zar FA, Bakkanagari SR, Moorthi KM, et al: A
comparison of vancomycin and metronidazole for the
treatment of Clostridium difficile-associated diarrhea,
stratiﬁed by disease severity. Clin Infect Dis 45:
302-307, 2007
28. Wenisch C, Parschalk B, Hasenhu¨ndl M, et al:
Comparison of vancomycin, teicoplanin, metronida-
zole, and fusidic acid for the treatment of Clostridium
difficile-associated diarrhea. Clin Infect Dis 22:
813-818, 1996 [Erratum: Clin Infect Dis 23:423, 1996]
29. Teasley DG, Gerding DN, Olson MM, et al:
Prospective randomised trial of metronidazole versus
vancomycin for Clostridium-difficile-associated di-
arrhoea and colitis. Lancet 2:1043-1046, 1983
30. Boix V, Fedorak RN,Mullane KM, et al: Primary
outcomes from a phase 3, randomized, double- blind,
active-controlled trial of surotomycin in subjects with
Clostridium difficile infection. Open Forum Infect Dis
4:ofw275, 2017
31. Lee CH, Patino H, Stevens C, et al: Sur-
otomycin versus vancomycin for Clostridium difficile
infection: Phase 2, randomized, controlled, double-
blind, non-inferiority, multicentre trial. J Antimicrob
Chemother 71:2964-2971, 2016
32. Daley P, Louie T, Lutz JE, et al: Surotomycin
versus vancomycin in adults with Clostridium difficile
infection: Primary clinical outcomes from the second
pivotal, randomized, double-blind, phase 3 trial.
J Antimicrob Chemother 72:3462-3470, 2017
33. Varier RU, Biltaji E, Smith KJ, et al: Cost-
effectiveness analysis of treatment strategies for
initial Clostridium difficile infection. Clin Microbiol
Infect 20:1343-1351, 2014
34. Guery B, Menichetti F, Anttila VJ, et al:
Extended-pulsed ﬁdaxomicin versus vancomycin for
Clostridium difficile infection in patients 60 years and
older (EXTEND): A randomised, controlled, open-label,
phase 3b/4 trial. Lancet Infect Dis 18:296-307, 2018
35. Cornely OA, Crook DW, Esposito R, et al:
Fidaxomicin versus vancomycin for infection with
Clostridium difficile in Europe, Canada, and the USA:
A double-blind, non-inferiority, randomised controlled
trial. Lancet Infect Dis 12:281-289, 2012
36. Louie TJ, Miller MA, Mullane KM, et al:
Fidaxomicin versus vancomycin for Clostridium dif-
ficile infection. N Engl J Med 364:422-431, 2011
37. Housman ST, Thabit AK, Kuti JL, et al: As-
sessment of Clostridium difficile burden in patients
over time with ﬁrst episode infection following
ﬁdaxomicin or vancomycin. Infect Control Hosp
Epidemiol 37:215-218, 2016
38. Cammarota G, Masucci L, Ianiro G, et al:
Randomised clinical trial: Faecal microbiota trans-
plantation by colonoscopy vs. vancomycin for the
treatment of recurrent Clostridium difficile infection.
Aliment Pharmacol Ther 41:835-843, 2015
39. Hota SS, Sales V, Tomlinson G, et al: Oral
vancomycin followed by fecal transplantation versus
tapering oral vancomycin treatment for recurrent
3170 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Diorio et al
Downloaded from ascopubs.org by UNIVERSITAETSSPITAL University BERN on February 19, 2019 from 130.092.009.058
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
Clostridium difficile infection: An open-label, ran-
domized controlled trial. Clin Infect Dis 64:265-271,
2017
40. van Nood E, Vrieze A, Nieuwdorp M, et al:
Duodenal infusion of donor feces for recurrent
Clostridium difficile. N Engl J Med 368:407-415, 2013
41. Wilcox MH, Gerding DN, Poxton IR, et al:
Bezlotoxumab for prevention of recurrent Clostrid-
ium difficile infection. N Engl J Med 376:305-317,
2017
42. Leav BA, Blair B, Leney M, et al: Serum anti-
toxin B antibody correlates with protection from re-
current Clostridium difficile infection (CDI). Vaccine
28:965-969, 2010
43. Lowy I, Molrine DC, Leav BA, et al: Treatment
with monoclonal antibodies against Clostridium dif-
ficile toxins. N Engl J Med 362:197-205, 2010
44. Lewis S, Burmeister S, Cohen S, et al: Failure of
dietary oligofructose to prevent antibiotic-associated
diarrhoea. Aliment Pharmacol Ther 21:469-477, 2005
45. Wullt M, Hagsla¨tt ML, Odenholt I: Lacto-
bacillus plantarum 299v for the treatment of re-
current Clostridium difficile-associated diarrhoea:
a double-blind, placebo-controlled trial. Scand J
Infect Dis 35:365-367, 2003
46. McFarland LV, Surawicz CM, Greenberg RN,
et al: A randomized placebo-controlled trial of Sac-
charomyces boulardii in combination with standard
antibiotics for Clostridium difficile disease. JAMA
271:1913-1918, 1994
47. Lehrnbecher T, Sung L: Anti-infective pro-
phylaxis in pediatric patients with acute myeloid
leukemia. Expert Rev Hematol 7:819-830, 2014
48. US Food and Drug Administration: Drug Ap-
proval Package: Zinplava Injection (bezlotoxumab).
https://www.accessdata.fda.gov/drugsatfda_docs/nda/
2016/761046_toc.cfm. Accessed May 2018
49. European Medicines Agency: Zinplava (bezlo-
toxumab). http://www.ema.europa.eu/ema/index.jsp?
curl=pages/medicines/human/medicines/004136/
human_med_002062.jsp&mid=WC0b01ac058001d124.
Accessed May 2018
Affiliations
Caroline Diorio, Paula D. Robinson, and Sandra Cabral, Pediatric Oncology Group of Ontario; Caroline Diorio, L. Lee Dupuis,
and Lillian Sung, The Hospital for Sick Children; L. Lee Dupuis, University of Toronto, Toronto; Caroline Diorio, McMaster Children’s
Hospital, Hamilton; Susan Kuczynski, Ontario Parents Advocating for Children with Cancer, Barrie, Ontario, Canada; Roland A.
Ammann, Bern University Hospital, University of Bern, Bern, Switzerland; Elio Castagnola, Istituto Giannina Gaslini, Genova, Italy;
Kelley Erickson and Brian T. Fisher, University of Pennsylvania, Children’s Hospital of Philadelphia, Philadelphia, PA; Adam
Esbenshade, Vanderbilt-Ingram Cancer Centre, Nashville, TN; Gabrielle M. Haeusler, Peter MacCallum Cancer Centre, Melbourne;
Gabrielle M. Haeusler, Royal Children’s Hospital, Parkville; Gabrielle M. Haeusler, Paediatric Integrated Cancer Service, Victoria,
Australia; Thomas Lehrnbecher, Hospital for Children and Adolescents, JohannWolfgang Goethe University, Frankfurt, Germany;Robert
Phillips, Leeds Teaching Hospital, National Health Service Trust, Leeds; and Robert Phillips, University of York, York, United Kingdom.
Support
Funded by the Pediatric Oncology Group of Ontario.
The funder did not have any inﬂuence over the content of this manuscript or the decision to submit for publication.
n n n
jco.org © 2018 by American Society of Clinical Oncology 3171
Pediatric Cancer C. Difficile Infection Guideline
Downloaded from ascopubs.org by UNIVERSITAETSSPITAL University BERN on February 19, 2019 from 130.092.009.058
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Guideline for the Management of Clostridium Difﬁcile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell
Transplantation Recipients
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are
self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more
information about ASCO’s conﬂict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.
Caroline Diorio
No relationship to disclose
Paula D. Robinson
No relationship to disclose
Roland A. Ammann
No relationship to disclose
Elio Castagnola
Speakers’ Bureau: Astellas Pharma
Kelley Erickson
No relationship to disclose
Adam Esbenshade
No relationship to disclose
Brian T. Fisher
Research Funding: Pﬁzer (Inst), Merck (Inst)
Gabrielle M. Haeusler
No relationship to disclose
Susan Kuczynski
No relationship to disclose
Thomas Lehrnbecher
Honoraria: Gilead Sciences, Astellas Pharma, Merck Sharp & Dohme
Consulting or Advisory Role: Gilead Sciences, Astellas Pharma, Merck
Sharp & Dohme
Speakers’ Bureau: Gilead Sciences, Astellas Pharma, Merck Sharp &
Dohme
Research Funding: Gilead Sciences
Travel, Accommodations, Expenses: Gilead Sciences, Astellas Pharma,
Merck Sharp & Dohme
Robert Phillips
No relationship to disclose
Sandra Cabral
No relationship to disclose
L. Lee Dupuis
Consulting or Advisory Role: Jazz Pharmaceuticals
Research Funding: Jazz Pharmaceuticals
Lillian Sung
No relationship to disclose
© 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Diorio et al
Downloaded from ascopubs.org by UNIVERSITAETSSPITAL University BERN on February 19, 2019 from 130.092.009.058
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
